CJC-1295: Sustained Growth Hormone for Body Composition
CJC-1295 takes an anabolic approach to body composition:
GHRH Analogue: CJC-1295 mimics Growth Hormone Releasing Hormone with a significantly extended half-life, producing sustained GH elevation.
IGF-1 Amplification: Sustained GH release stimulates hepatic IGF-1 production, mediating GH's anabolic effects — muscle protein synthesis, fat oxidation, and bone mineralisation.
Body Composition: CJC-1295 shifts body composition towards lean mass by supporting protein synthesis and lipolysis simultaneously.
ORYN Format: €109 for a 30-day pen with 5mg pharmaceutical-grade CJC-1295.
Semaglutide vs Tirzepatide: Why ORYN Chose Tirzepatide
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. ORYN offers Tirzepatide instead:
Semaglutide (GLP-1 Only): Clinical trials (STEP-1) showed 14.9% weight loss at 68 weeks.
Tirzepatide (GIP + GLP-1): SURPASS-2 showed Tirzepatide outperformed Semaglutide at all doses, with SURMOUNT-1 showing up to 20.9% weight loss.
ORYN Tirzepatide Options: Standard pen (10mg, €169) or MediT Pen (40mg, €249) for weekly administration.
CJC-1295 or Metabolic Peptides: Which Approach?
Choose CJC-1295 if: - Your focus is growth hormone biology - You want to improve body composition via anabolic pathways - Recovery, sleep quality, and tissue repair are research endpoints - Budget is a factor (€109 is the most affordable option)
Choose Tirzepatide if: - Weight management is the primary research endpoint - Appetite regulation and caloric intake reduction are being studied - Metabolic syndrome or insulin sensitivity is relevant - You want the most clinically validated weight loss approach
